KKR provides Slayback Pharma a $60M financing round
January 06, 2017
Drug Discovery | Princeton Junction, NJ | PE Growth
KKR has invested $60 million in pharmaceutical researcher and developer Slayback Pharma to help accelerate development of the company's products. KKR’s Neel Varshney and Ali Satvat will join the Slayback board as part of the deal.